1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancerMariangela Saggese, Jonathan Krell, Douglas Cartwright et al.|Annals of Oncology|2025Cited by 1